Cited by 258Antifungal resistance and susceptibilityFungal Plant Pathogen ControlBacterial Identification and Susceptibility Testing

The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.

Correlation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints

Open access

Pfaller, M. A., Diekema, D. J., Rex, J. H., Espinel-Ingroff, A., Johnson, E. M., Andes, D., Chaturvedi, V., Ghannoum, M. A, Odds, F. C., Rinaldi, M. G., Sheehan, D. J., Troke, P., Walsh, T. J., Warnock, D. W.·2006·Journal of Clinical Microbiology

DOI 10.1128/jcm.44.3.819-826.2006PMC PMC1393146

Open this paper in CoChat — free account

Abstract

Developing interpretive breakpoints for any given organism-drug combination requires integration of the MIC distribution, pharmacokinetic and pharmacodynamic parameters, and the relationship between the in vitro activity and outcome from both in vivo and clinical studies. Using data generated by standardized broth microdilution and disk diffusion test methods, the Antifungal Susceptibility Subcommittee of the Clinical and Laboratory Standards Institute has now proposed interpretive breakpoints for voriconazole and Candida species. The MIC distribution for voriconazole was determined using a collection of 8,702 clinical isolates. The overall MIC 90 was 0.25 μg/ml and 99% of the isolates were inhibited at ≤1 μg/ml of voriconazole. Similar results were obtained for 1,681 Candida isolates (16 species) from the phase III clinical trials. Analysis of the available data for 249 patients from six phase III voriconazole clinical trials demonstrated a statistically significant correlation ( P = 0.021) between MIC and investigator end-of-treatment assessment of outcome. Consistent with parallel pharmacodynamic analyses, these data support the following MIC breakpoints for voriconazole and Candida species: susceptible (S), ≤1 μg/ml; susceptible dose dependent (SDD), 2 μg/ml; and resistant (R), ≥4 μg/ml. The corresponding disk test breakpoints are as follows: S, ≥17 mm; SDD, 14 to 16 mm; and R, ≤13 mm.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1128/jcm.44.3.819-826.2006

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · PEDIATRICS · doi:10.1542/peds.65.1.187 · Cited by 14,736
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Self-citation
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : Approved standard
Wikler, M. A., & Clinical (2006) · Clinical and Laboratory Standards Institute eBooks · Cited by 2,842
Antibiotics in Laboratory Medicine.
Lorian, V. (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-4-653_4 · Cited by 2,809
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Self-citation
Voriconazole Compared with Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Neutropenia and Persistent Fever
Walsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460403 · Cited by 979
Self-citation
Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida Infections
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Self-citation
Rare and Emerging Opportunistic Fungal Pathogens: Concern for Resistance beyondCandida albicansandAspergillus fumigatus
Pfaller, M. A., & Diekema, D. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.10.4419-4431.2004 · Cited by 705
Self-citation
Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections
Perfect, J. R., Marr, K. A., Walsh, T. J., Greenberg, R. N., Dupont, B., Torre‐Cisneros, J., Just‐Nübling, G., Schlamm, H. T., Lutsar, I., Espinel‐Ingroff, A., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374557 · Cited by 676
Self-citation

Flagged first, then by citations

Show all 43 references

1 of the 43 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Florea, N. R., J. L. Kuti, and R. Quintiliani. 2002. Voriconazole: a novel azole antifungal. Formulary37:389-399.

Sorted by citations

Items 101–200 of 258

Multilaboratory Testing of Two-Drug Combinations of Antifungals againstCandida albicans,Candida glabrata, andCandida parapsilosis
Chaturvedi, V. P., Ramani, R., Andes, D. R., Diekema, D. J., Pfaller, M. A., Ghannoum, M. A., Knapp, C. C., Lockhart, S. R., Ostrosky‐Zeichner, L., Walsh, T. J., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01510-09 · Cited by 46
Self-citation
Pharmacokinetics and Pharmacodynamics of Antibacterials, Antifungals, and Antivirals Used Most Frequently in Neonates and Infants
Roberts, J. K., Stockmann, C. R., Constance, J. E., Stiers, J., Spigarelli, M. G., Ward, R. M., & Sherwin, C. M. T. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0147-0 · Cited by 46
A case of endocarditis caused by the yeastPichia fabianiiwith biofilm production and developedin vitroresistance to azoles in the course of antifungal treatment
Hamal, P., Ostřanský, J., Dendis, M., Horváth, R., Růžička, F., Buchta, V., Vejsová, M., Sauer, P., Hejnar, P., & Raclavský, V. (2008) · Medical Mycology · doi:10.1080/13693780802078180 · Cited by 43
Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies
Johnson, E. M., Espinel‐Ingroff, A., Székely, A., Hockey, H. P., & Troke, P. F. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.05.023 · Cited by 43
Self-citation
Antifungals in the ICU
Playford, E. G., Eggimann, P., & Calandra, T. (2008) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3283177967 · Cited by 42
Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole
Moriyama, B., Kadri, S. S., Henning, S. A., Danner, R. L., Walsh, T. J., & Penzak, S. R. (2015) · Current Fungal Infection Reports · doi:10.1007/s12281-015-0219-0 · Cited by 42
Self-citation
Identification and antifungal susceptibility of a large collection of yeast strains isolated in Tunisian hospitals
Eddouzi, J., Lohberger, A., Vogne, C., Manaï, M., & Sanglard, D. (2013) · Medical Mycology · doi:10.3109/13693786.2013.800239 · Cited by 39
Role of antifungal susceptibility testing in patient management
Forrest, G. N. (2006) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328010682c · Cited by 39
Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study
Myrianthefs, P. M., Markantonis, S. L., Evagelopoulou, P., Despotelis, S., Evodia, E., Panidis, D., & Baltopoulos, G. I. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.12.021 · Cited by 39
Antimicrobial resistance prevention initiative—an update: Proceedings of an expert panel on resistance
Moellering, R. C., Graybill, J. R., McGowan, J. E., & Corey, L. (2007) · American Journal of Infection Control · doi:10.1016/j.ajic.2007.08.001 · Cited by 38
Sensibilidad a fluconazol y voriconazol de especies de Candida aisladas de pacientes provenientes de unidades de cuidados intensivos en Medellín, Colombia (2001–2007)
Zuluaga, A., Gómez, C. D. B., Restrepo, C. A. A., Parra, H. H., Arteaga, M. A., Moreno, Á. R., & Marín, Á. G. (2010) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2010.04.001 · Cited by 38
Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values
Pfaller, M. A., Diekema, D. J., Procop, G. W., & Rinaldi, M. G. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2013.05.019 · Cited by 37
Self-citation
Epidemiology of candidaemia in critically ill trauma patients: experiences of a level I trauma centre in North India
Singh, R., Xess, I., Mathur, P., Behera, B., Gupta, B., & Misra, M. (2010) · Journal of Medical Microbiology · doi:10.1099/jmm.0.023739-0 · Cited by 37
In Vitro Antifungal Activities of Isavuconazole and Comparators against Rare Yeast Pathogens
Guinea, J., Recio, S., Escribano, P., Peláez, T., Gama, B., & Bouza, E. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00685-10 · Cited by 37
High incidence of Candida parapsilosis candidaemia in non-neutropenic critically ill patients: Epidemiology and antifungal susceptibility
Dizbay, M., Fidan, I., Kalkancı, A., Sarı, N., Yalçin, B., Kuştımur, S., & Arman, D. (2009) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365540903321572 · Cited by 35
Effects of Antifungal Agents in Sap Activity of Candida albicans Isolates
Costa, C. R., Jesuíno, R. S. A., Lemos, J. D. A., Fernandes, O. D. F. L., Souza, L. K. H. E., Passos, X. S., & Silva, M. D. R. R. (2009) · Mycopathologia · doi:10.1007/s11046-009-9232-6 · Cited by 35
Validation of 24-Hour Posaconazole and Voriconazole MIC Readings versus the CLSI 48-Hour Broth Microdilution Reference Method: Application of Epidemiological Cutoff Values to Results from a Global Candida Antifungal Surveillance Program
Pfaller, M. A., Boyken, L. B., Hollis, R. J., Kroeger, J. S., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02437-10 · Cited by 34
Self-citation
Rapid identification of fungal pathogens in positive blood cultures using oligonucleotide array hybridization
Hsiue, E. H.-C., Huang, Y., Kuo, Y.-L., Liao, C., Chang, T.-C., & Hsueh, P. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.02828.x · Cited by 33
Pharmacokinetic and Pharmacodynamic Properties of Oral Voriconazole in Patients with Invasive Fungal Infections
Wang, T., Xie, J., Wang, Y., Zheng, X., Lei, J., Wang, X., Dong, H., Yang, Q., Chen, L., Xing, J., et al. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1631 · Cited by 33
Antifungal Drug Susceptibility Profile of Pichia anomala Isolates from Patients Presenting with Nosocomial Fungemia
da Matta, V. L. R., Melhem, M. D. S. C., Colombo, A. L., Moretti, M. L., Rodero, L., de Almeida, G. M. D., Martins, M. D. A., Costa, S. F., Dias, M. B. S., Nucci, M., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01038-06 · Cited by 34
Antifungal Susceptibility of Bloodstream Candida Isolates in Sfax Hospital: Tunisia
Sellami, A., Sellami, H., Néji, S., Makni, F., Abbes, S., Cheikhrouhou, F., Chelly, H., Bouaziz, M., Hammami, B., Jemâa, M. B., et al. (2010) · Mycopathologia · doi:10.1007/s11046-010-9388-0 · Cited by 32
Peritonitis due to Neosartorya pseudofischeri in an elderly patient undergoing peritoneal dialysis successfully treated with voriconazole
Ghebremedhin, B., Bluemel, A., Neumann, K. H., Koenig, B., & Köenig, W. (2009) · Journal of Medical Microbiology · doi:10.1099/jmm.0.005785-0 · Cited by 32
Fabrication of hydrophobic drug-loaded Zeolitic Imidazolate Framework-8 (ZIF-8) for enhanced anti-bacterial activity
Pandey, S. K., Sharmah, B., Manna, P., Chawngthu, Z., Kumar, S., Trivedi, A. K., Saha, S. K., & Das, J. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.138452 · Cited by 31
Fluorosis Because of Prolonged Voriconazole Therapy in a Teenager With Acute Myelogenous Leukemia
Skiles, J. L., Imel, E. A., Christenson, J. C., Bell, J. E., & Hulbert, M. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.9604 · Cited by 30
Fluconazole exposure rather than clonal spreading is correlated with the emergence of Candida glabrata with cross‐resistance to triazole antifungal agents
Chen, T., Chen, Y., Chen, Y., & Lu, P. (2012) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/j.kjms.2011.11.011 · Cited by 30
In Vitro Susceptibility of a Large Collection of Candida Strains Against Fluconazole and Voriconazole by Using the CLSI Disk Diffusion Assay
Azevedo, A. C., Bizerra, F. C., da Matta, D. A., de Almeida, L. P., Rosas, R., & Colombo, A. L. (2010) · Mycopathologia · doi:10.1007/s11046-010-9387-1 · Cited by 30
In Vitro Susceptibilities of Invasive Isolates of Candida Species: Rapid Increase in Rates of Fluconazole Susceptible-Dose Dependent Candida glabrata Isolates
Ruan, S., Chu, C., & Hsueh, P. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00323-08 · Cited by 28
In vitro fluconazole and nystatin susceptibility and clinical outcome in complicated vulvovaginal candidosis
Fan, S., & Liu, X. P. (2010) · Mycoses · doi:10.1111/j.1439-0507.2010.01887.x · Cited by 29
Clinical relevance of resistance to antifungals
Rodrı́guez-Tudela, J. L., Alcázar‐Fuoli, L., Cuesta, I., Alastruey‐Izquierdo, A., Monzón, A., Mellado, E., & Cuenca‐Estrella, M. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(08)70010-4 · Cited by 29
Evaluation of Disk Diffusion and Etest Compared to Broth Microdilution for Antifungal Susceptibility Testing of Posaconazole against Clinical Isolates of Filamentous Fungi
Messer, S. A., Diekema, D. J., Hollis, R. J., Boyken, L. B., Tendolkar, S., Kroeger, J. S., & Pfaller, M. A. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.02450-06 · Cited by 29
Self-citation
Characterization of Hwp2, a Candida albicans putative GPI-anchored cell wall protein necessary for invasive growth
Hayek, P., Dib, L., Yazbeck, P., Beyrouthy, B., & Khalaf, R. A. (2009) · Microbiological Research · doi:10.1016/j.micres.2009.03.006 · Cited by 29
Caspofungin activity against clinical isolates of azole cross-resistant Candida glabrata overexpressing efflux pump genes
Posteraro, B. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl237 · Cited by 27
Fluconazole susceptibility and ERG11 gene expression in vaginal candida species isolated from Lagos Nigeria.
Pam, V., Akpan, J. U., Oduyebo, O. O., Nwaokorie, F. O., Fowora, M. A., Oladele, R. O., Ogunsola, F. T., & Smith, S. I. (2012) · PubMed Central · Cited by 27
Trends in frequency and in vitro antifungal susceptibility patterns of Candida isolates from women attending the STD outpatients clinic of a tertiary care hospital in Northern Italy during the years 2002-2007.
Asticcioli, S., Sacco, L., Daturi, R., Matti, C., Nucleo, E., Zara, F., & Pagani, L. (2009) · PubMed · Cited by 27
The relationship between antifungal usage and antifungal susceptibility in clinical isolates ofCandida: a multicenter Korean study
Kim, S. H., Shin, J. H., Kim, E. C., Lee, K., Kim, M., Lee, W. G., Uh, Y., Lee, H. S., Lee, M., Jeong, S. H., et al. (2008) · Medical Mycology · doi:10.1080/13693780802291445 · Cited by 27
Candida rugosa: a possible emerging cause of candidaemia in trauma patients
Behera, B., Singh, R. I., Xess, I., Mathur, P., Hasan, F., & Misra, M. (2010) · Infection · doi:10.1007/s15010-010-0044-x · Cited by 26
Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program
Pfaller, M. A., Boyken, L. B., Hollis, R. J., Kroeger, J. S., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2009) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2009.05.007 · Cited by 26
Self-citation
The impact of azole resistance on aspergillosis guidelines
Georgiadou, S. P., & Kontoyiannis, D. P. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06795.x · Cited by 25
Distribution of voriconazole in seven body fluids of adult horses after repeated oral dosing
PASSLER, N. H., Chan, H. M., Stewart, A. J., Duran, S. H., Welles, E. G., Lin, H., & Ravis, W. R. (2009) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/j.1365-2885.2009.01099.x · Cited by 25
Frequency of Voriconazole Resistance In Vitro among Spanish Clinical Isolates of Candida spp. According to Breakpoints Established by the Antifungal Subcommittee of the European Committee on Antimicrobial Susceptibility Testing
Cuenca‐Estrella, M., Gómez‐López, A., Cuesta, I., Zaragoza, Ó., Mellado, E., & Rodríguez-Tudela, J. L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01757-10 · Cited by 25
Interpersonal Factors in the Pharmacokinetics and Pharmacodynamics of Voriconazole: Are CYP2C19 Genotypes Enough for Us to Make a Clinical Decision?
Zhong, X., Tong, X., Ju, Y., Du, X., & Li, Y. (2018) · Current Drug Metabolism · doi:10.2174/1389200219666171227200547 · Cited by 25
A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp.
Diekema, D. J., Messer, S. A., Hollis, R. J., Boyken, L. B., Tendolkar, S., Kroeger, J. S., Jones, R. N., & Pfaller, M. A. (2008) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2008.11.001 · Cited by 25
Self-citation
Genomics and the development of new diagnostics and anti-Candida drugs
Weig, M., & Brown, A. J. P. (2007) · Trends in Microbiology · doi:10.1016/j.tim.2007.05.007 · Cited by 25
Assessment of Accuracy of Identification of Pathogenic Yeasts in Microbiology Laboratories in the United Kingdom
Borman, A. M., Székely, A., Palmer, M. D., & Johnson, E. M. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00913-12 · Cited by 24
Self-citation
Épidémiologie des candidémies : étude observationnelle prospective d’un an dans l’Ouest de la France
Talarmin, J. P., Boutoille, D., Tattevin, P., Dargère, S., Weinbreck, P., Ansart, S., Chennebault, J. M., Hutin, P., Leautez-Nainville, S., Gay‐Andrieu, F., et al. (2009) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2009.02.008 · Cited by 24
Voriconazole: A Broad Spectrum Triazole for the Treatment of Serious and Invasive Fungal Infections
Maschmeyer, G., & Haas, A. (2006) · Future Microbiology · doi:10.2217/17460913.1.4.365 · Cited by 24
Superficial candidosis by Candida duobushaemulonii: An emerging microorganism
León, M. G. F.-D., Martínez-Herrera, E. O., Acosta‐Altamirano, G., Arenas, R. G., & Rodríguez‐Cerdeira, C. (2019) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2019.103960 · Cited by 24
Invasive candidiasis in the ICU: evidence based and on the edge of evidence
Hollenbach, E. (2008) · Mycoses · doi:10.1111/j.1439-0507.2008.01571.x · Cited by 24
Antifungal Resistance of Candida glabrata Vaginal Isolates and Development of a Quantitative Reverse Transcription-PCR-Based Azole Susceptibility Assay
Gygax, S. E., Vermitsky, J., Chadwick, S. G., Self, M. J., Zimmerman, J. A., Mordechai, E., Adelson, M. E., & Trama, J. P. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00462-08 · Cited by 24
Catheter-related fungemia caused by Candida intermedia
Ruan, S., Chien, J., Hou, Y.-C., & Hsueh, P. (2009) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2009.03.015 · Cited by 24
Construction of BODIPY functional ZIF-8 with improved visible light-induced antibacterial activity
Shen, Z., Qu, L., Kan, X.-L., Chen, Q., He, G., & Sun, M. (2022) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2022.128835 · Cited by 23
Study of Pathogens of Fungal Keratitis and the Sensitivity of Pathogenic Fungi to Therapeutic Agents with the Disk Diffusion Method
Wang, L., Wang, L., Han, L., & Yin, W. (2015) · Current Eye Research · doi:10.3109/02713683.2015.1056802 · Cited by 23
Antifungal PK/PD Considerations in Fungal Pulmonary Infections
Lepak, A. J., & Andes, D. R. (2011) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0031-1295726 · Cited by 23
Self-citation
Prevalence of Candida species in different hospital wards and their susceptibility to antifungal agents: results of a three year survey
Fadda, M. E., Podda, G., Pisano, M. B., Deplano, M., & Cosentino, S. (2015) · Journal of preventive medicine and hygiene · doi:10.15167/2421-4248/jpmh2008.49.2.119 · Cited by 23
Candidaemia and antifungal susceptibility testing in a teaching hospital.
Tzar, M. N., & Shamim, A. (2009) · PubMed · Cited by 22
Candida glabrata fungaemia in a tertiary centre in Taiwan: antifungal susceptibility and outcomes
Ruan, S., Huang, Y., Chu, C.-C., Yu, C., & Hsueh, P. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.02.021 · Cited by 21
Activity of Combined Antifungal Agents Against Multidrug-Resistant Candida glabrata Strains
Denardi, L. B., Keller, J. T., Oliveira, V., Mario, D. A. N., Santúrio, J. M., & Alves, S. H. (2017) · Mycopathologia · doi:10.1007/s11046-017-0141-9 · Cited by 21
Antifungal Effects on Metabolite Profiles of Medically Important Yeast Species Measured by Nuclear Magnetic Resonance Spectroscopy
Coen, M., Bodkin, J. A., Power, D., Bubb, W. A., Himmelreich, U., Kuchel, P. W., & Sorrell, T. C. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00439-06 · Cited by 21
Antifungal Activity of Itraconazole and Voriconazole against Clinical Isolates Obtained from Animals with Mycoses
Okabayashi, K., Imaji, M., Osumi, T., Murakami, Y., Maruyama, H., Kano, R., Hasegawa, A., & WATANABE, T. (2009) · Nippon Ishinkin Gakkai Zasshi · doi:10.3314/jjmm.50.091 · Cited by 21
Treatment of Invasive Candidiasis in Immunocompromised Pediatric Patients
Fisher, B. T., & Zaoutis, T. E. (2008) · Pediatric Drugs · doi:10.2165/00148581-200810050-00003 · Cited by 20
Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trial
Mootsikapun, P., Hsueh, P., Talwar, D., Co, V. M., Rajadhyaksha, V., & Ong, M. (2013) · BMC Infectious Diseases · doi:10.1186/1471-2334-13-219 · Cited by 20
Co-Administration with Voriconazole Doubles the Exposure of Ruxolitinib in Patients with Hematological Malignancies
Zhao, Y., Chen, P., Dou, L., Li, F., Li, M., Xu, L., Chen, J., Jia, M., Huang, S., Wang, N., et al. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s354270 · Cited by 19
Yeasts isolated from nosocomial urinary infections: Antifungal susceptibility and biofilm production
de Freitas, A. R., Baeza, L. C., Faria, M. G. I., Dota, K. F. D., Godoy-Martinez, P. C., & Svidzinski, T. I. E. (2013) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2013.06.004 · Cited by 20
EUCAST and CLSI: How to Assess in Vitro Susceptibility and Clinical Resistance
Alastruey‐Izquierdo, A., & Cuenca‐Estrella, M. (2012) · Current Fungal Infection Reports · doi:10.1007/s12281-012-0100-3 · Cited by 19
Fluconazole resistance in Candida glabrata is associated with increased bud formation and metallothionein production
Samaranayake, Y. H., Cheung, B. P. K., Wang, Y., Yau, J. Y. Y., Yeung, K. W. S., & Samaranayake, L. P. (2012) · Journal of Medical Microbiology · doi:10.1099/jmm.0.044123-0 · Cited by 18
Evaluation of the VITEK 2 system to test the susceptibility of Candida spp., Trichosporon asahii and Cryptococcus neoformans to amphotericin B, flucytosine, fluconazole and voriconazole: a comparison with the M27-A3 reference method
Cejudo, M. T. G., Gallego, A. G., Lacasa, E. C., Aller, A. I., Romero, A., Pemán, J., Quindós, G., & Martín‐Mazuelos, E. (2010) · Medical Mycology · doi:10.3109/13693780903473343 · Cited by 18
Commercial Methods for Antifungal Susceptibility Testing of Yeasts: Strengths and Limitations as Predictors of Resistance
Espinel‐Ingroff, A. (2022) · Journal of Fungi · doi:10.3390/jof8030309 · Cited by 19
Self-citation
Diagnostics of fungal infections in the Nordic countries: We still need to improve!
Arendrup, M. C., Chryssanthou, E., Gaustad, P., Koskela, M., Sandven, P., & Fernandez, V. (2006) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540601071859 · Cited by 18
Are In Vitro Susceptibilities to Azole Antifungals Predictive of Clinical Outcome in the Treatment of Candidemia?
Patel, T. S., Carver, P. L., & Eschenauer, G. A. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01072-18 · Cited by 17
Fungal exposure endocrinopathy in sinusitis with growth hormone deficiency: Dennis-Robertson syndrome
Dennis, D. P., Robertson, D. G. C., Curtis, L. T., & Black, J. (2009) · Toxicology and Industrial Health · doi:10.1177/0748233709348266 · Cited by 16
Cryptococcus neoformans serotype A and Cryptococcus gattii serotype B isolates differ in their susceptibilities to fluconazole and voriconazole
Khan, Z., Randhawa, H. S., Chehadeh, W., Chowdhary, A., Kowshik, T., & Chandy, R. G. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.11.007 · Cited by 16
Virulence and susceptibility patterns of clinical Candida spp. isolates from a tertiary hospital, Tanzania
Mushi, M. F., Bader, O., Bii, C. C., Groß, U., & Mshana, S. E. (2018) · Medical Mycology · doi:10.1093/mmy/myy107 · Cited by 17
Antifungal Resistance Testing and Implications for Management
Badali, H., & Wiederhold, N. P. (2019) · Current Fungal Infection Reports · doi:10.1007/s12281-019-00354-6 · Cited by 16
Invasive Candida infections in children: the clinical characteristics and species distribution and antifungal susceptibility of Candida spp
Belet, N., Çi̇ftçi̇, E., Aysev, D., Güri̇z, H., Uysal, Z., Taçyildiz, N., Atasay, B., Doğu, F., Kendirli, T., Kuloğlu, Z., et al. (2011) · The Turkish Journal of Pediatrics · doi:10.24953/turkjpediatr.2011.1807 · Cited by 15
Pharmacokinetic–pharmacodynamic optimization of triazole antifungal therapy
Lewis, R. E. (2011) · Current Opinion in Infectious Diseases · doi:10.1097/01.qco.0000399603.91138.e7 · Cited by 14
Measurement of Voriconazole Activity against Candida albicans , C. glabrata , and C. parapsilosis Isolates Using Time-Kill Methods Validated by High-Performance Liquid Chromatography
Li, Y., Nguyen, M. H., Derendorf, H., Cheng, S., & Clancy, C. J. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00308-07 · Cited by 14
Optimization of voriconazole dosage regimen to improve the efficacy in patients with invasive fungal disease by pharmacokinetic/pharmacodynamic analysis
Chen, L., Wang, T., Wang, Y., Yang, Q., Xie, J., Li, Y., Lei, J., Wang, X., Xing, J., Dong, Y., et al. (2016) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12212 · Cited by 13
In Vitro Susceptibility Testing in Fungi: What is its Role in Clinical Practice?
Perkhofer, S., Mrazek, C., Hartl, L., & Lass‐Flörl, C. (2010) · Current Infectious Disease Reports · doi:10.1007/s11908-010-0134-z · Cited by 12
Evaluation of fungaemia infections in a Hungarian university hospital between 1996 and 2009
Dóczi, I., Pető, Z., Fodor, E., Bereczki, L., Nagy, E., & Hajdú, E. (2012) · Acta Microbiologica et Immunologica Hungarica · doi:10.1556/amicr.59.2012.1.4 · Cited by 12
Distribution of Yeast Isolates from Invasive Infections and Their In Vitro Susceptibility to Antifungal Agents: Evidence from 299 Cases in a 3-Year (2010 to 2012) Surveillance Study
Li, W., Hu, Y., Li, F., Shi, L.-N., Shao, H., Huang, M., Wang, Y., Han, D., Liao, H., Chun-fang, M., et al. (2015) · Mycopathologia · doi:10.1007/s11046-015-9858-5 · Cited by 11
Actividad antifúngica in vitro de voriconazol: Nuevos datos después de los primeros años de experiencia clínica
Quindós, G., Carrillo‐Muñoz, A. J., Eraso, E., Cantón, E., & Pemán, J. (2007) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(07)70043-8 · Cited by 11
New antifungal agents for the treatment of candidaemia
Muñóz, P., Guinea, J., Rojas, L., & Bouza, E. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.11.007 · Cited by 10
Vulvovaginal candidiasis in pregnant women attending a tertiary care centre in North-Eastern India
Roy, M., Majumdar, T., & Ray, J. (2024) · Indian Journal of Medical Microbiology · doi:10.1016/j.ijmmb.2024.100738 · Cited by 10
Species Distribution andin VitroSusceptibility ofCandidaBloodstream Isolates to Six New and Current Antifungal Agents in a Turkish Tertiary Care Military Hospital, Recovered Through 2001 and 2006
Saraçlı, M. A., Gümral, R., Gül, H. C., Gönlüm, A., & Yıldıran, Ş. T. (2009) · Military Medicine · doi:10.7205/milmed-d-04-7808 · Cited by 9
Candida infection in the intensive care unit: A study of antifungal susceptibility pattern of Candida species in Milad hospital, Tehran, Iran
Alimehr, S., Abad, H. S. E., Fallah, F., Rahbar, M., Mohammadzadeh, M., Vossoghian, S., Tabatabaee, S., Roudbary, M., & Zaini, F. (2015) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2015.09.005 · Cited by 10
Invasive Fungal Infections and Approaches to Their Diagnosis
Pfaller, M. A. (2015) · Methods in microbiology · doi:10.1016/bs.mim.2015.05.002 · Cited by 11
Self-citation
Chapter 31 Plasma Protein Binding and the Free Drug Principle: Recent Developments and Applications
Trainor, G. L. (2007) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(07)42031-0 · Cited by 10
Propofol lipidic infusion promotes resistance to antifungals by reducing drug input into the fungal cell
Costa‐de‐Oliveira, S., Araújo, R., Silva-Dias, A., Pina‐Vaz, C., & Rodrigues, A. G. (2008) · BMC Microbiology · doi:10.1186/1471-2180-8-9 · Cited by 10
Antifungal Susceptibility ofCandidaSpecies Using the Clinical and Laboratory Standards Institute Disk Diffusion and Broth Microdilution Methods
Noake, T., Kuriyama, T., White, P. L., Potts, A. J. C., Lewis, M. A. O., Williams, D. W., & Barnes, R. A. (2007) · Journal of Chemotherapy · doi:10.1179/joc.2007.19.3.283 · Cited by 10
Antifungals: Drug Class, Mechanisms of Action, Pharmacokinetics/Pharmacodynamics, Drug-Drug Interactions, Toxicity, and Clinical Use
Nett, J. E., & Andes, D. R. (2014) · ASM Press eBooks · doi:10.1128/9781555817176.ch22 · Cited by 10
Self-citation
Activity of Caspofungin and Voriconazole against Clinical Isolates of Candida and Other Medically Important Yeasts by the CLSI M-44A Disk Diffusion Method with Neo-Sensitabs Tablets
Carrillo‐Muñoz, A. J., Quindós, G., del Valle, O., Santos, P., Giusiano, G., Ezkurra, P. A., Estivill, M. D., & Casals, J. B. (2007) · Chemotherapy · doi:10.1159/000112414 · Cited by 10
Antifungal Susceptibility Testing
Leber, A. L. (2016) · ASM Press eBooks · doi:10.1128/9781555818814.ch8.10.1 · Cited by 10
Expression of ERG11 and efflux pump genes CDR1, CDR2 and SNQ2 in voriconazole susceptible and resistant Candida glabrata strains
Navarro-Rodríguez, P., Martín‐Vicente, A., López‐Fernández, L., Guarro, J., & Capilla, J. (2019) · Medical Mycology · doi:10.1093/mmy/myz014 · Cited by 10
Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for Candida albicans Using a Validated In Vitro Pharmacokinetic/Pharmacodynamic Model
Beredaki, M.-I., Georgiou, P., Siopi, M., Kanioura, L., Andes, D. R., Arendrup, M. C., Mouton, J. W., & Meletiadis, J. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00170-20 · Cited by 9
Self-citation
Utility of Antifungal Susceptibility Testing and Clinical Correlations
Diekema, D. J., & Pfaller, M. A. (2011) · Humana Press eBooks · doi:10.1007/978-1-59745-134-5_8 · Cited by 9
Self-citation
[Nosocomial candidemia: new challenges of an emergent problem].
Gómez, J. G., Vázquez, E. G., Hernández, A., Espinosa, C., & Pardo, J. R. (2010) · PubMed · Cited by 13
New developments in the antifungal susceptibility testing of Candida
Pfaller, M. A. (2008) · Current Fungal Infection Reports · doi:10.1007/s12281-008-0019-x · Cited by 9
Self-citation
Laboratory Aspects of Medical Mycology
Brandt, M. E., Lockhart, S. R., & Warnock, D. W. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6640-7_1 · Cited by 10
Self-citation
Mechanisms of Resistance to Antifungal Agents
White, T. C., & Hoot, S. J. (2011) · Wiley eBooks · doi:10.1128/9781555816728.ch127 · Cited by 9
Plasma Protein Binding and Volume of Distribution: Determination, Prediction and Use in Early Drug Discovery
Lombardo, F., Obach, R. S., & Waters, N. J. (2009) · Methods and principles in medicinal chemistry · doi:10.1002/9783527627448.ch9 · Cited by 9

Authors: Pfaller, M. A., Diekema, D. J., Rex, J. H., Espinel-Ingroff, A., Johnson, E. M., Andes, D., Chaturvedi, V., Ghannoum, M. A., Odds, F. C., Rinaldi, M. G., Sheehan, D. J., Troke, P., Walsh, T. J., & Warnock, D. W.
Affiliations: University of Iowa (US)
AstraZeneca (United Kingdom) (GB)
VCU Medical Center, Richmond, Virginia
HPA Centre for Infections, Kingsdown, Bristol, United Kingdom
University of Wisconsin–Madison (US)
New York State Department of Health (US)
Case Western Reserve University (US)
University of Aberdeen (GB)
The University of Texas at San Antonio Health Science Center (US)
Pfizer (United States) (US)
Pfizer (United Kingdom) (GB)
National Institutes of Health (US)
Centers for Disease Control and Prevention (US)
Corresponding author: Pfaller, M. A.
ORCID: Pfaller, M. A.
Diekema, D. J.
Rex, J. H.
Johnson, E. M.
Andes, D.
Chaturvedi, V.
Ghannoum, M. A
Walsh, T. J.
Venue: Journal of Clinical Microbiology
Publisher: American Society for Microbiology
Published: 2006-03
Volume: 44
Issue: 3
Pages: 819-826
ISSN: 0095-1137 (ISSN-L)
1098-660X
DOI: 10.1128/jcm.44.3.819-826.2006
PMC: PMC1393146
OpenAlex: W2138433856
Cited by: 258
References: 43
Citations by year: 2026: 4 · 2025: 3 · 2024: 4 · 2022: 4 · 2021: 2 · 2020: 2 · 2019: 4 · 2018: 4 · 2017: 3 · 2016: 3 · 2015: 12 · 2014: 8 · 2013: 5 · 2012: 16
FWCI: 25.48
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: journals.asm.org/non-commercial-tdm-license (tdm)
Locations: Journal of Clinical Microbiology (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Pfizer
Topics: Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
Keywords: voriconazole, Candida species, interpretive breakpoints, minimum inhibitory concentration, antifungal susceptibility, MIC distribution, antifungal resistance
MeSH terms: Antifungal Agents, Candida, Candidiasis, Data Interpretation, Statistical, Humans, Microbial Sensitivity Tests, Pyrimidines, Triazoles, Fluconazole, Inhibitory Concentration 50, Endpoint Determination, Drug Resistance, Fungal, Voriconazole

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Correlation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks